EFSA sets out its challenges and objectives for the next five years
This article was originally published in RAJ Devices
Executive Summary
Better responsiveness, reinforcing public confidence and timely delivery of scientific opinions are just a few of six objectives outlined in the recently released European Food Safety Authority’s (EFSA’s) Draft Strategic Plan 2009-2013. The Plan outlines EFSA’s scientific direction for the next five years, enabling the authority to establish its priorities in light of an evolving environment. Following a discussion on the Plan during the latest EFSA Management Board meeting, the authority has launched a public consultation on the document
You may also be interested in...
Inspired by EU Strategy, EFSA sets out goals for contributing to animal health in Europe
With a view to strengthening its integrated approach towards animal health, the European Food Safety Authority (EFSA) has set itself six goals that it will pursue in the near future. The inspiration for the recent authority paper in which the goals have been set down, is the current EU Animal Health Strategy for 2007-2013. EFSA believes that it is uniquely positioned to adopt an integrated approach to animal health, taking into account the relationship between animal welfare, animal diseases and food safety – areas that are all within the authority’s remit.
Denmark combats fear-mongering emails on EU food supplement legislation
The Danish Medicines Agency (Lægemiddelstryrelsen) has found itself in the uncomfortable position of having to warn the public against two wholly misleading chain emails about restrictions on the sale of dietary supplements.
Russian pharma strategy cheers domestic firms but is criticised by state purse-keeper
The Russian ministry for economy and energy has finalised the draft: “Strategy for the development of the pharmaceutical industry in the Russian Federation until 2020”, on which it has been working since the beginning of this year. The draft – presently being discussed by the country’s cabinet – has already been criticised by the ministry of finance, raising fears among domestic drug manufacturers that the Russian pharmaceutical industry will not see any significant results from the document’s implementation.